Advertisement
U.S. markets open in 1 hour 9 minutes
S&P Futures
5,874.25 -22.00 (-0.37%) Dow Futures
43,039.00 -138.00 (-0.32%) Nasdaq Futures
20,432.75 -86.75 (-0.42%) Russell 2000 Futures
2,244.20 -11.30 (-0.50%) Crude Oil
71.17 +0.61 (+0.86%) Gold
2,748.30 +9.40 (+0.34%)
Dr. Reddy's Laboratories Limited (DRREDDY.NS)
NSE - NSE Real Time Price. Currency in INR
Follow
At close: 03:30PM IST
| Previous Close | 6,697.40 |
| Open | 6,727.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 6,632.30 - 6,755.00 |
| 52 Week Range | 5,205.55 - 7,107.45 |
| Volume | |
| Avg. Volume | 374,335 |
| Market Cap | 1.11T |
| Beta (5Y Monthly) | 0.31 |
| PE Ratio (TTM) | 19.98 |
| EPS (TTM) | 333.53 |
| Earnings Date | Nov 05, 2024 |
| Forward Dividend & Yield | 40.00 (0.60%) |
| Ex-Dividend Date | Jul 16, 2024 |
| 1y Target Est | 6,172.76 |
Business WireDr. Reddy’s Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month
PRINCETON, N.J., October 14, 2024--Dr. Reddy’s launches comprehensive menopause support program and training for employees during menopause awareness month.
TipRanksDr. Reddy’s Subsidiary Triumphs in CAR-T Cell Therapy Trial
Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s subsidiary Aurigene Oncology Limited reports positive Phase 1 results for India’s first novel CAR-T cell therapy trial in multiple myeloma patients. The therapy, Ribrecabtagene autoleucel, showed a 100% clinical response rate without any high-grade safety concerns, paving the way for the Phase 2 trial with regulatory approval. These findings could mark a significant advancement in treatment options for Indian myeloma patients. For
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.